Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation...

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Viz.ai’s AI Algorithm for Abdominal Aorti...

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm On March 21, 2023, Viz.ai, the leader in AI-powered disease detection and intelligent care coordinatio...

Mar 23, 2023

Pharma News and Updates for AbbVie, Arrowhead Pharma, Novartis, FORE Biotherapeutics, Ellipses Pharma, Karuna Therapeutics
AbbVie Announces Results of Study Evaluating SKYRIZI; FDA Fast Track Designation to Arrowhead’s ARO-APOC3; FDA Approves Dabrafenib Plus Trametinib for BRAF V600E–Mutated Low-Grade Glioma; FDA Grants ODD to Novel BRAF Inhibitor for Brain/CNS Malignancies; EP0042 Wins FDA Orphan Drug Status; Karuna Therapeutics Announces Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

AbbVie Announces Positive Results of Study Evaluating SKYRIZI in Plaque Psoriasis Patients AbbVie announced new 52-week data from an open-label, a single-arm study demonstrating improved plaque psoriasis signs and symptoms in a difficult-to-treat patient population who received SKYRIZI® (risankizumab), an IL-23 ...

Find More
MedTech News and Update for Sight Sciences, HeartBeam, LIVMOR, Occlutech, PADM Medical, Kardium, LivaNova
Sight Sciences’s Ergo-Series of the OMNI® Surgical System; HeartBeam to Acquire LIVMOR’s Assets; Occlutech Atrial Flow Regulator (FROST-HF) Study Updates; US FDA 510(k) Clearance for PADM Medical’s PRECISION ECO; Kardium ‘s Pulsed-Field Ablation Study; US FDA 510(k) Clearance for LivaNova’s Essenz Heart-Lung Machine

Ergo-Series of the OMNI® Surgical System Launched by Sight Sciences On March 9, 2023, Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology, providing solutions for transforming care and improving patients' lives, announced the launch of the Ergo-Seri...

Find More
Pharma news and updates for Roche, Acadia, Shorla Oncology, Calliditas, Mesoblast, Sanofi, Provention Bio
Sanofi to Acquire Provention Bio; USFDA Committee Votes in Favor Roche’s Polivy; FDA to Review Mesoblast’s GvHD Drug; FDA Approves Acadia’s Daybue ; FDA Approves Nelarabine Injection; Calliditas’s Nefecon Trial Reuslt in IgA Nephropathy

Sanofi to Acquire Provention Bio for USD 2.9 Billion Sanofi and Provention Bio, Inc., a publicly traded biopharmaceutical company based in the United States focused on intercepting and preventing immune-mediated diseases such as type 1 diabetes (T1D), have agreed to acquire Provention Bio, Inc. for $25.00 per sh...

Find More

More Views & Analysis

MedTech News for Artica Systems, Nevro, Stratus® Medical, Restore Medical, Respiree, Abbott
Artica Systems’s Electric Whole-Body Cryotherapy Machines; Nevro’s Revolutionary HFX iQ™ Spinal Cord Stimulation System; COBRA Study of Stratus® Medical for Nimbus® Radiofrequency Ablation Device; Restore Medical’s CONTRABAND™ System; US FDA 510(k) Clearance for RS001 Cardio-respiratory Wearable; FDA Approval to Abbott’s Traumatic Brain Injury (TBI) Blood Test

New Commercial & Residential Electric Whole-Body Cryotherapy Machines Released by Artica Systems  On March 2, 2023, Artica Systems, an American company with over 20 years of experience in the wellness industry announced the release of a new and innovative 100% electric, whole-body cryotherapy fleet mean...

Find More

Pharma News and Updates for Incyte, Eisai, Biogen, Reata Pharmaceuticals, Genenta Science, Harbour BioMed, Ikena Oncology
Incyte’s Clinical Trial for Myelofibrosis; Eisai and Bioge’s Leqembi; FDA Approves Reata Pharmaceuticals’ SKYCLARYS; Temferon Lands FDA Orphan Drug Status for Glioblastoma; Harbour BioMed Announces Results from Phase III Trial of Batoclimab; FDA Fast Track Designation to Ikena’s AHR Antagonist IK-175

Incyte Halts Phase III Clinical Trial for Myelofibrosis  Incyte announced the termination of Phase III LIMBER-304 trial after the results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) revealed that the study is unlikely to meet the primary endpoint in the int...

Find More

MedTech News and Updates for SOPHiA GENETICS, QIAGEN, Co-Diagnostics, Abbott, SpectraWAVE, Bioelectronic Medicine
Eko’s AI-powered Sensora Platform; SOPHiA GENETICS and QIAGEN Announced Partnership; Co-Diagnostics’s At-Home and Point-of-Care Co-Dx PCR Home™ Platform; Abbott’s Minimally Invasive Heart Devices Updates; SpectraWAVE’s HyperVue™ Intravascular Imaging System; FDA Approval to Bioelectronic Medicine’s Bioelectric Technology

AI-powered Sensora Platform Launched by Eko for Cardiac Disease Detection On February 23, 2023, Eko, a digital healthcare company employing artificial intelligence (AI) against heart and lung disease, announced the launch of its SENSORA™ Cardiac Disease Detection Platform. The stethoscope, one of the m...

Find More

Pharma News and Updates for SpringWorks Therapeutics, AskBio, Mitsubishi Tanabe Pharma America, Sage Therapeutics, Biohaven Pharma
SpringWorks’s Desmoid Tumors Therapeutic, Nirogacestat; Orphan Drug Designation to AskBio’s AB-1003; Mitsubishi Tanabe’s Phase 3 Trial of RADICAVA ORS in ALS; EU Orphan Drug Designation to Sage Therapeutics’s SAGE-718; FDA Fast Track Status to Biohaven’s Taldefgrobep Alfa

Sage Therapeutics Receives EU Orphan Drug Designation for Huntington's Disease Treatment Candidate Sage Therapeutics declared the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is developing as a potential oral therapy for cognitive disor...

Find More

MedTech News and Updates for Medtronic, Stryker, Dexcom, Rhaeos, Synchrony
Medtronic’s Extravascular Defibrillator System; Stryker’s Q Guidance System for Cranial Applications; Synchrony Medical’s LibAirty™ Airway Clearance System Study; Cognito Therapeutics’s Pivotal Study HOPE Update; Dexcom’s G6 Continuous Glucose Monitoring System Launch in Singapore; Rhaeos Raised $10.5M in Series A Funding

Medtronic Received CE Mark for Extravascular Defibrillator System, used to treat Abnormal Heart Rhythms On February 17, 2023, Medtronic plc, the leading global healthcare technology company, received CE mark for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator)...

Find More

Pharma News and Updates for Actinium, Apellis, Chiesi, IVERIC, Travere, Takeda
Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results

Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older...

Find More

Myocardial Infarction
Myocardial Infarction...

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More
Acute Ischemic Stroke (AIS)
Acute Ischemic Stroke (AI...

Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....

Find More
Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More